Item 2.02 Results of Operations and Financial Condition.

On January 11, 2022, Mirum Pharmaceuticals, Inc. (the "Company") issued a press release announcing, among other things, the Company's preliminary unaudited revenues for both the quarter and fiscal year ended December 31, 2021. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On January 11, 2022, in connection with its participation in the J.P. Morgan Healthcare Conference, the Company posted a corporate slide presentation in the "Investors" portion of its website at www.mirumpharma.com. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.

The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



Exhibit
  No.        Description

99.1           Press Release dated January 11, 2022

99.2           Investor Presentation dated January 2022

104          Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses